Trevi Therapeutics, Inc. is a drug development company founded in 2011 focused on developing T111 for the severe chronic itching condition known as pruritus. Pruritus is manifested in various dermatological, metabolic, hematologic and neuronal conditions. The Company is pursuing uremic pruritus as the lead indication. Uremic pruritus is a persistent and debilitating itching in patients on dialysis that has been linked to increased mortality. T111 is an oral extended release opioid with a unique dual agonist/antagonist mechanism of action, which has been shown in both animal and human clinical studies as being effective in pruritus.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 12/18/12 | $10,000,000 | Series A |
TPG Biotech | undisclosed |
| 06/04/14 | $25,000,000 | Series B |
TPG Biotech | undisclosed |
| 07/20/17 | $50,500,000 | Series C |
Aperture Venture Partners Lundbeckfonden Ventures Omega Funds TPG Biotech | undisclosed |
